USFDA conducted an inspection at Zydus Lifesciences Limited's manufacturing facility SEZ-1 at Pharmez, Ahmedabad from March 20 to March 24, 2023, the company announced through an exchange filing. The inspection was a pre-approval inspection (PAI) and a GMP Audit that concluded with three observations.
The company said that there were no data integrity related observations and the company is addressing these observations.
Zydus received final approval from USFDA for Lubiprostone Capsules, the company announced on March 24.
Zydus Lifesciences shares
Bombay HC Raps Govt Over Kanjurmarg Dumping Ground Pollution; Orders DCM-Led Meeting On Dec 2 To Address Citizen Complaints
Hong Kong High-Rise Blaze: Death Toll Rises To 36, 279 Missing; Xi Jinping Extends Condolences As Fire Engulfs Multiple Towers | VIDEO
Second FIR Against Folk Singer Neha Singh Rathore In Lucknow Over Alleged Communal Social Media Posts
Maharashtra Raj Bhavan Observes Constitution Day With Collective Preamble Reading
The shares of Zydus Lifesciences on Friday closed at Rs 480.05, down by 0.47 per cent.
